EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide

Christina Maria Flies iD, Michel Friedrich, Philipp Lohmann iD, Karin Alida van Garderen, Marion Smits iD, Joerg-Christian Tonn, Michael Weller iD, Norbert Galldiks iD, Tom Jan Snijders iD

Neuro-Oncology · 03.05.2024 · 26 (5) · 902-910

DOI: 10.1093/neuonc/noad247 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neuro-Oncology, online erschienen am 14.01.2024. Verfasst von Christina Maria Flies und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology & Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Glioblastoma, Snake Venoms, Brain Neoplasms, DNA Modification Methylases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Stophersenkanker.nu foundation, Foundation Vrienden UMC Utrecht.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Radiological progression may originate from progressive disease (PD) or pseudoprogression/treatment-associated changes. We assessed radiological progression in O6-methylguanine-DNA methyltransferase (MGMT) promoter-methylated glioblastoma treated with standard-of-care chemoradiotherapy with or without the integrin inhibitor cilengitide according to the modified response assessment in neuro-oncology (RANO) criteria of 2017.

Methods

Patients with ≥ 3 follow-up MRIs were included. Preliminary PD was defined as a ≥ 25% increase of the sum of products of perpendicular diameters (SPD) of a new or increasing lesion compared to baseline. PD required a second ≥25% increase of the SPD. Treatment-associated changes require stable or regressing disease after preliminary PD.

Results

Of the 424 evaluable patients, 221 patients (52%) were randomized into the cilengitide and 203 patients (48%) into the control arm. After chemoradiation with or without cilengitide, preliminary PD occurred in 274 patients (65%) during available follow-up, and 88 of these patients (32%) had treatment-associated changes, whereas 67 patients (25%) had PD. The remaining 119 patients (43%) had no further follow-up after preliminary PD. Treatment-associated changes were more common in the cilengitide arm than in the standard-of-care arm (24% vs. 17%; relative risk, 1.3; 95% CI, 1.004–1.795; P = .047). Treatment-associated changes occurred mainly during the first 6 months after RT (54% after 3 months vs. 13% after 6 months).

Conclusions

With the modified RANO criteria, the rate of treatment-associated changes was low compared to previous studies in MGMT promoter-methylated glioblastoma. This rate was higher after cilengitide compared to standard-of-care treatment. Confirmatory scans, as recommended in the modified RANO criteria, were not always available reflecting current clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaSnake VenomsBrain NeoplasmsDNA Modification MethylasesChemoradiotherapyDNA Repair EnzymesPromoter Regions, GeneticDNA MethylationTumor Suppressor ProteinsHumansFemaleMaleMiddle AgedAgedAdultMagnetic Resonance ImagingFollow-Up StudiesDisease ProgressionPrognosisAged, 80 and over

Stichwörter der Autor:innen

gliomamodified RANO criteriapseudoprogressiontemozolomide

Substanzen

CilengitideSnake VenomsDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanTumor Suppressor Proteins

Autor:innen und Institutionen

  • Department of Neurology & Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
  • Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Brain Tumour Centre, Erasmus MC Cancer Centre, Rotterdam, The Netherlands.
  • Medical Delta, Delft, The Netherlands.
  • Department of Neurosurgery, University Hospital Munich LMU, Munich, Germany.

ORCID-Profile: Christina Maria Flies, Philipp Lohmann, Marion Smits, Michael Weller, Norbert Galldiks, Tom Jan Snijders

Förderung

  • the Stophersenkanker.nu foundation
  • Foundation Vrienden UMC Utrecht

Zitieren

APA

Flies, C. M., Friedrich, M., Lohmann, P., van Garderen, K. A., Smits, M., Tonn, J. C., Weller, M., Galldiks, N., & Snijders, T. J. (2024). Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide. Neuro-Oncology, 26(5), 902-910. https://doi.org/10.1093/neuonc/noad247

Vancouver

Flies CM, Friedrich M, Lohmann P, van Garderen KA, Smits M, Tonn JC, et al. Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide. Neuro-Oncology. 2024;26(5):902-910. doi:10.1093/neuonc/noad247

BibTeX
@article{Flies2024,
  author = {Flies, Christina Maria and Friedrich, Michel and Lohmann, Philipp and van Garderen, Karin Alida and Smits, Marion and Tonn, Joerg-Christian and Weller, Michael and Galldiks, Norbert and Snijders, Tom Jan},
  title = {Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {5},
  pages = {902--910},
  doi = {10.1093/neuonc/noad247}
}
Kostenlos starten →